Gilead Sciences’ subsidiary Kite Pharma has announced the acquisition of Interius BioTherapeutics, a privately held biotech company, for USD 350 million in cash. The deal is aimed at advancing Kite’s development of in vivo CAR-T cell therapies, considered a next-generation approach to cancer treatment.

Unlike traditional CAR-T therapies that require extracting, engineering, and reinfusing T cells back into patients, Interius’s in vivo technology allows therapeutic DNA to be delivered directly into the body through intravenous infusion. This model has the potential to simplify manufacturing, lower costs, and significantly expand patient access to cell therapy.

The acquisition, pending regulatory approvals, is expected to reduce Gilead's 2025 earnings per share by approximately USD 0.23–0.25. Following the closure of the deal, Interius’s operations and team will be integrated into Kite’s Philadelphia research hub.

Industry experts note that in vivo CAR-T therapies represent one of the most promising areas in biotech, attracting over USD 2 billion in investments globally. With several programs already in clinical development and more than 100 assets projected by the end of 2025, the acquisition positions Gilead at the forefront of a transformative wave in cell and gene therapy.